Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Alternative Names: PMN 330; PMN 350; PMN-310; TDP 43 targeting therapeutics

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Preclinical Alzheimer's disease; Dementia
  • Research Down syndrome; Lewy body disease; Parkinson's disease
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Canada (Parenteral)
  • 30 Sep 2017 Early research in Lewy body disease in Canada (Parenteral)
  • 30 Sep 2017 Early research in Parkinson's disease in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top